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OBJECTIVES This study was designed to compare the long-term consequences of percutaneous translu-
minal coronary angioplasty (PTCA) and continued medical treatment.
BACKGROUND The long-term effects of percutaneous coronary intervention need evaluating, especially in
comparison with an alternative policy of continued medical treatment.
METHODS The Second Randomized Intervention Treatment of Angina (RITA-2) is a randomized trial
of PTCA versus conservative (medical) care in 1,018 patients considered suitable for either
treatment option. Information on clinical events, interventions, and symptoms is available for
a median seven years follow-up.
RESULTS Death or myocardial infarction (MI) occurred in 73 (14.5%) PTCA patients and 63 (12.3%)
medical patients (difference 2.2%, 95% confidence interval 2.0% to 6.4%, p  0.21).
There were 43 deaths in both groups, of which 41% were cardiac-related. Among patients
assigned PTCA 12.7% subsequently had coronary artery bypass grafts, and 14.5% required
additional non-randomized PTCA. Most of these re-interventions occurred within a year of
randomization, and after two years the re-intervention rate was 2.3% per annum. In the
medical group, 35.4% required myocardial revascularization: 15.0% in the first year and an
annual rate of 3.6% after two years. An initial policy of PTCA was associated with improved
anginal symptoms and exercise times. These treatment differences narrowed over time, mainly
because of coronary interventions in medical patients with severe symptoms.
CONCLUSIONS In RITA-2 an initial strategy of PTCA did not influence the risk of death or MI, but it
improved angina and exercise tolerance. Patients considered suitable for PTCA or medical
therapy can be safely managed with continued medical therapy, but percutaneous intervention
is appropriate if symptoms are not controlled. (J Am Coll Cardiol 2003;42:1161–70)
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The optimal management of patients with angina pectoris
remains controversial, but options include anti-anginal
medication, percutaneous coronary intervention (PCI), or
coronary artery bypass surgery. Several randomized clinical
trials have compared percutaneous and surgical methods of
See page 1171
myocardial revascularization, and some have reported long-
term results (1–3). Overall, these trials suggest that percu-
taneous intervention is slightly less effective at relieving
angina than is coronary artery bypass surgery, but there is no
evidence that either revascularization strategy provides a
prognostic advantage in the majority of patients.
For some patients with angina, revascularization is not
considered essential for symptom relief or for prognostic
reasons. Several small trials have compared percutaneous
intervention with alternative medical treatment strategies in
such patients, but most have reported only limited
follow-up data (4–8). A meta-analysis of data available in
1998 concluded that percutaneous transluminal coronary
angioplasty (PTCA) provides superior relief of angina at the
cost of more coronary artery bypass surgery, but it could not
reliably estimate the effects of the two treatment strategies
on the risk of death or myocardial infarction (MI) (9).
The second Randomized Intervention Treatment of An-
gina (RITA-2) trial was designed to compare PTCA with
continued medical treatment in patients in whom either
strategy was considered a clinically acceptable treatment
option. The primary trial end point was the five-year rate of
death or non-fatal MI. The trial recruited 1,018 patients,
and interim results have been published (10,11). In this
article we report extended follow-up of the RITA-2 patients
to a median seven years.
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METHODS
Trial design. The design of RITA-2 has been reported
previously (10). Patients were recruited at 20 centers in the
U.K. and Ireland, and the ethics committee of each partic-
ipating center approved the trial protocol. In brief, patients
with arteriographically proven coronary artery disease
(CAD) were considered for the trial if the supervising
cardiologist thought that continued medical therapy and
PTCA were both acceptable treatment options. Patients
had to be over 18 years of age, but there was no upper age
limit. Patients were not required to have current symptoms,
but patients with multi-vessel disease, occluded coronary
arteries, or impaired left ventricular (LV) function were
potentially eligible for the trial. Patients with previous
myocardial revascularization, significant left main stem dis-
ease, recent (within seven days) acute coronary syndrome,
hemodynamically significant valve disease, or life-
threatening non-cardiac disease likely to have a major
influence on survival were excluded. Patients in whom
revascularization was considered necessary for symptom
relief or for prognostic reasons were also ineligible.
Before randomization, a participating interventional car-
diologist reviewed the coronary arteriogram of a potentially
eligible patient and identified at least one significant coro-
nary stenosis in a major epicardial vessel that could be
treated by coronary angioplasty. Patients who satisfied the
eligibility criteria and consented to participate were subse-
quently randomized to initial treatment strategies of PTCA
or continued medical management. Patients were stratified
by center and by extent of disease (single or multi-vessel
disease).
The trial protocol required that patients assigned to
PTCA underwent dilation of the target stenosis (or steno-
ses) within three months of randomization. Stents and other
coronary interventional techniques were used only if the
initial balloon angioplasty result was unsatisfactory. The
choice of medication after a randomized PTCA was not
mandated, although clinicians were encouraged to discon-
tinue anti-anginal drugs if a patient no longer had symp-
toms of angina. Patients in the PTCA group underwent
additional coronary arteriography and revascularization pro-
cedures if considered appropriate by the supervising clini-
cian, with the objective of detecting and treating restenosis.
Patients randomized to an initial strategy of medical
management were prescribed appropriate anti-anginal med-
ication for symptom relief. Coronary arteriography was
repeated only for compelling clinical reasons, and myocar-
dial revascularization procedures were reserved for patients
whose symptoms were not controlled by optimal anti-
anginal medication (usually a beta-adrenoceptor blocker,
with a calcium antagonist, and/or with long-acting nitrate
in maximally tolerated doses).
Data collection. Patients were assessed at three months,
six months, and yearly intervals after randomization. Re-
search assistants at each participating center recorded trial
data on specially prepared forms.
The pre-defined primary trial end point was the five-year
rate of death and definite MI. An independent event
validation committee, unaware of treatment assignment,
reviewed all available information on deaths and MIs. The
cause of death was classified as cardiac, other cardiovascular,
or non-cardiovascular. Definite MI was diagnosed when
new pathological Q-waves appeared on a follow-up electro-
cardiogram, or when a convincing clinical history was
associated with electrocardiographic changes consistent
with non–Q-wave infarction and cardiac enzyme activity
above twice the upper limit of normal on at least two
relevant serum samples.
As previously reported, angina was assessed with the
Canadian Cardiovascular Society classification and breath-
lessness and physical activity were assessed by ordinal scales
(10,12). Symptom-limited exercise tolerance tests were
carried out using the Bruce protocol at three and six months
and one and three years after randomization. Left ventric-
ular function was assessed from LV angiograms using a wall
motion score.
Statistical analysis. A total of 1,018 patients were random-
ized at 20 participating centers. All data were analyzed by
intention to treat, using standard methods. The percentages
of patients with the primary end point of death or MI at five
years in each treatment group were compared using Kaplan-
Meier estimates. Times to death and death/MI are pre-
sented using Kaplan-Meier curves. The percentages of
patients reporting other outcomes from follow-up inter-
views were compared using chi-squared tests. Analysis of
co-variance was used to compare exercise time at three
months and three years. Prognostic factors were determined
by forward stepwise regression modeling: for the outcome of
cardiac death or non-fatal MI, Cox regression was used, and
for angina grade 2 at five years, logistic regression was
used.
RESULTS
The 1,018 patients were randomized to coronary angio-
plasty (n  504) or continued medical treatment (n  514)
from July 1992 to May 1996. Follow-up to September 30,
2001, is included in this report, the median follow-up
period being seven years. Eighteen patients (1.8%) have
been lost to follow-up. The five-year follow-up rate is
99.1%.
Abbreviations and Acronyms
CABG  coronary artery bypass graft
CAD  coronary artery disease
LV  left ventricular
MI  myocardial infarction
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary angioplasty
RITA  Randomized Intervention Treatment of
Angina
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Baseline data and randomized PTCA. Detailed informa-
tion on baseline comparability and the randomized PTCA
has been published earlier (10). In brief, 60% of patients had
single-vessel disease, 53% had angina grade 2 or worse, 18%
were female, and the median age was 58 years. At random-
ization 53% were receiving two or more anti-anginal drugs,
13% were taking lipid-lowering medication, 47% had had a
previous MI, and 9% were treated for diabetes. The PTCA
and medical treatment groups were similar with regard to all
these baseline features.
The intended randomized PTCA was performed on 471
(93%) patients in the PTCA group, the median time from
randomization to PTCA being five weeks. Angioplasty was
attempted in a mean 1.4 vessel segments per patient (means
1.2, 1.6, and 1.9 segments for those with significant disease
in 1, 2, and 3 epicardial vessels, respectively), of which 93%
were successfully dilated. The randomized PTCA was
complicated by emergency coronary artery bypass graft
(CABG) in seven patients, non-fatal MI in seven patients
(of whom 4 developed new electrocardiographic Q-waves),
and one procedure-related death. Patient recruitment began
before the widespread use of coronary stents, which were
implanted during 44 (9%) randomized PTCAs. Of these,
32 occurred in the 160 patients randomized to PTCA
during 1995 and 1996, the last 17 months of patient
recruitment.
Death and MI. To date, 43 patients have died in both
treatment groups (Table 1). The survival plot (Fig. 1A)
reveals comparable mortality between groups over eight
years of follow-up. At five years follow-up, the mortality
rate was 4.6% and 4.7% in the PTCA and medical groups,
respectively (difference 0.1%, 95% confidence interval
[CI] 2.7% to 2.5%).
Almost half the deaths were from non-cardiovascular
causes. Although there were fewer cardiac deaths in the
PTCA group—13 PTCA versus 22 medical—this differ-
ence is not statistically significant. Three of the seven
cardiovascular deaths in the PTCA group were due to
stroke.
To date, 32 and 23 patients in the PTCA and medical
groups respectively have had a definite non-fatal MI (Table
1), five of whom (2 PTCA, 3 medical) have subsequently
died. Thus, death or definite MI has occurred in 73 PTCA
and 63 medical patients. The time-to-event plot (Fig. 1B)
reveals an excess risk of this combined end point in the
PTCA group in the first two months after randomization,
which can be attributed to the eight procedure-related
events mentioned earlier. Thereafter, the plots run parallel
with a steady rate of end points up to eight years of
follow-up. If the eight events related to the randomized
PTCA are discounted, the subsequent rates of death or
definite MI in the PTCA and medical groups are 2.0 and
1.8 per 100 patient-years of follow-up, respectively (differ-
ence 0.2, 95% CI from 0.5 to 0.8).
The pre-defined primary end point of death or definite
Table 1. Deaths, MIs, and New Interventions During a Median
Seven Year Follow-Up
Outcome
PTCA
(n  504)
Medical
(n  514)
Deaths
Cardiac 13 22
Other cardiovascular 7 2
Non-cardiovascular 23 19
All causes 43 43
Definite non-fatal MI
Related to randomized PTCA 7 –
Related to other intervention 4 3
Other 21 20
Total 32 23
Death or definite MI (primary end point) 73 63
Cardiac death or definite MI 44 42
Patients with non-randomized
interventions (total number of
procedures in brackets)
CABG 64 (65) 63 (63)
Non-randomized PTCA 86 (106) 139 (174)
CABG and/or non-randomized PTCA 137 (171) 182 (237)
Coronary arteriography 191 (278) 182 (244)
CABG  coronary artery bypass graft; MI  myocardial infarction; PTCA 
percutaneous transluminal coronary angioplasty.
Figure 1. Cumulative risk of (A) death and (B) death or definite non-fatal
myocardial infarction (MI). Bars show 95% confidence interval. Numbers
show patients at risk of death or non-fatal MI. PTCA  percutaneous
transluminal coronary angioplasty.
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MI at five years (including procedure-related events) oc-
curred in 47 PTCA patients (9.4%) and 39 medical patients
(7.6%) (difference 1.8%, 95% CI 1.7% to 5.2%, p 
0.31).
Subsequent interventions. Since randomization, 64 pa-
tients randomized to PTCA (12.7%) and 63 (12.3%)
patients randomized to medical treatment have had CABGs
(Table 1). This includes the seven emergency CABGs after
randomized PTCA and nine CABGs performed instead of
the intended randomized PTCA.
In the PTCA group, additional non-randomized PTCA
was required in 86 patients, 13 of whom also had CABG
and 17 of whom required two or more such PTCAs. In the
medical group, 139 patients subsequently had a first PTCA,
of whom 20 also needed CABG during follow-up.
In total, the PTCA and medical groups had 106 and 174
non-randomized PTCAs during follow-up, and stents were
implanted during 36% of these procedures in each group.
Stent use increased over time: in 1992 to 1994, in 1995 to
1997, and in 1998 to 2001, the numbers of non-randomized
PTCAs with stent insertion are 9 of 94 (9.6%), 42 of 113
(37.2%), and 50 of 73 (68.5%), respectively. There was no
evidence of a difference in any outcome between patients
with stents and those without stents.
In both treatment groups, the rate of non-randomized
interventions (further PTCA and/or CABG) is much
higher in the first year of follow-up (Fig. 2). In the PTCA
group, 14.9% of patients required re-intervention in that
first year (one-third of whom required CABG). This fell to
a re-intervention rate of 3.8% in the next year and an
average of 2.3% per annum over years 3 to 8 post random-
ization. In the medical group, 15% of the patients under-
went a coronary intervention procedure in the first year
(one-fifth of whom required CABG). In year 2, this fell to
6.4%, and in years 3 to 8 their coronary intervention rate
averaged 3.6% per annum.
Over five years of follow-up, 10.5% of the PTCA group
had a CABG, compared to 9.3% in the medical group. In
the PTCA group, the five-year rate of re-intervention
(PTCA and/or CABG) was 23.3% (16.2% and 28.9%,
respectively, for patients with baseline angina grade 2 and
2). Information about coronary arteriography before these
non-randomized revascularization procedures was available
for 71 of 106 PTCA patients, and restenosis was demon-
strated in 63%. By contrast, in the medical group 28.8% of
patients had at least one coronary revascularization proce-
dure by five years (20.2% and 37.5%, respectively, for
patients with baseline angina grade 2 and 2), but 71.2%
did not require any revascularization procedure.
Angina and breathlessness. The prevalence of angina
declined in both treatment groups during the first five years
of follow-up (Fig. 3), but this symptomatic improvement
was much more rapid in the PTCA group. At three months
after randomization, 19.4% and 35.9% of the PTCA and
medical groups, respectively, had angina grade 2 or worse
(difference 16.5%, 95% CI 11.0% to 21.9%). By five years
follow-up, the prevalence of angina grade 2 or worse in the
PTCA group remained steady at 15.0%, whereas in the
medical group the prevalence of angina was reduced to
21.4%. The five-year treatment difference is thus much
smaller, 6.4% in favor of PTCA (95% CI 1.5% to 11.3%,
p  0.011). During the next three years, the prevalence of
angina begins to increase slightly in both treatment groups.
The above results are based on analysis by intention to
treat, but it is also relevant to consider the impact of
non-randomized procedures on anginal symptoms. Figure 4
relates mean angina grade to time before and after the first
non-randomized intervention; the vertical line at time 0
represents the moment of intervention. Patients without
non-randomized interventions are not shown on these
graphs. The angina grades are smoothed using a nearest-
neighbor running-line smoother, with the data before and
after the non-randomized intervention smoothed separately
to allow a discontinuity. Pointwise 95% confidence intervals
are also shown. The mean angina grade increases during the
6 to 12 months before the non-randomized intervention
(especially in the medical group), whether the intervention
is PTCA or CABG. The angina grade of patients imme-
diately before their non-randomized intervention was re-
corded only for patients in the medical group; the mean is
Figure 2. Non-randomized intervention rates by year of follow-up. CABG
 coronary artery bypass graft; PTCA  percutaneous transluminal
coronary angioplasty.
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marked with a triangle (Fig. 4) and is consistent with the
prior trend. After the non-randomized intervention, angina
grade improves rapidly, especially where a CABG was done
(Figs. 4B and 4D).
Patients in the PTCA group had less use of anti-anginal
drugs up to eight years follow-up compared with the
medical group. For instance, at five years 70% and 83% of
the PTCA and medical groups, respectively, were receiving
at least one anti-anginal drug, 23% and 34% were receiving
two drugs, and 8% and 11% were receiving triple-drug
therapy. Anti-anginal treatment included a beta-blocker in
42% of the PTCA group and 53% of the medical group. In
the PTCA group, 92% were taking aspirin, compared with
91% of the medical group. The use of HMG CoA reductase
inhibitors increased over time, and at five years 51% of the
PTCA group and 47% of the medical group were prescribed
lipid-lowering medication. Angiotensin-converting enzyme
inhibitors were prescribed for 20% of the PTCA group and
17% of the medical group.
The highly significant treatment difference in prevalence
of breathlessness in early follow-up had largely disappeared
after a few years: 42% versus 57% breathless at three months
(p  0.001) in the PTCA and medical groups, respectively,
compared to 46% versus 50% at three years (p  0.30).
Similarly the mean difference in Bruce exercise treadmill
time at three months,37 s in favor of PTCA based on 864
patients (95% CI 21 to 52 s), had reduced to 25 s mean
benefit based on 749 patients (95% CI 6 to 44 s) by three
years follow-up.
Prognostic factors. In determining which patient baseline
factors are linked to subsequent prognosis we considered
two outcomes:
1) The combined incidence of cardiac death and definite
non-fatal MI, excluding the eight such events related to
randomized PTCA, since they are likely to have a different
etiology. Thus 78 patients experienced this outcome.
2) The presence of angina grade 2 or worse five years after
randomization: this affected 173 of 948 patients seen at
five years.
For each outcome the following baseline factors were
considered: angina grade, unstable angina in the past three
months, number of anti-anginal drugs, breathlessness grade,
exercise treadmill time, age, gender, previous MI, treatment
for diabetes mellitus (with diet, drugs, or insulin), treatment
for hypertension, blood pressure, serum cholesterol, weight,
height, body mass index, smoking history, electrocardio-
graphic abnormality, LV function score, number of diseased
vessels, and 50% stenosis in the proximal left anterior
descending or other proximal vessel. By using forward
stepwise regression modeling procedures the predictive
models shown in Table 2 were derived.
For cardiac death and non-fatal MI, angina grade at
randomization was the strongest predictor. Patients with
both proximal left anterior descending and at least one other
diseased proximal vessel (i.e., 50% stenosis) had an esti-
mated three-fold increase in risk, but there were only 71
patients in this category. There was no treatment difference
in risk after adjusting for these two factors.
For prevalence of angina grade 2 after five years, the
baseline exercise time and breathlessness at baseline were
strongly predictive. Patients with more severe angina at
baseline also had an increased risk; but angina grade was
strongly associated with breathlessness and exercise time,
and after taking these variables into account, baseline angina
grade was less independently predictive of outcome. After
adjusting for these three factors, there remained a 33% odds
reduction in angina at five years for PTCA versus medical
treatment (p  0.031).
Figure 3. Prevalence of angina over time at baseline (base), three, and six months, and yearly intervals after randomization. P coronary angioplasty group;
M  medical group.
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There was a trend for the 90 patients with diabetes
mellitus to be at greater risk of death or MI (hazard ratio
1.17, 95% CI 0.56 to 2.43) or angina grade 2 during
follow-up (odds ratio 1.43, 95% CI 0.80 to 2.58), but there
was no evidence of an interaction between diabetes and
treatment for these two outcomes. Other subgroup analyses
were explored for each of the baseline variables listed above,
but for neither outcome were there any statistically signifi-
cant interactions between treatment group and baseline
factors.
DISCUSSION
The RITA-2 trial provides the only currently available
randomized evidence comparing the long-term conse-
quences of PCI and medical treatment in patients with
Figure 4. Mean angina grades before and after non-randomized intervention. Panels A and B show data for the percutaneous transluminal coronary
angioplasty (PTCA) group. Panels C and D show data for the medical group. Lines are smoothed averages and 95% confidence intervals. The circles show
individual data points. Continued on next page.
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angina. Over a median seven years follow-up, we have
demonstrated that initial policies of PTCA and medical
therapy in patients considered suitable for either treatment
are comparable with regard to risk of death and non-fatal
MI, but an initial policy of PTCA was associated with a
lower prevalence of angina and improved exercise tolerance.
The patients in our trial were selected from a large group
of patients undergoing coronary arteriography and ranged
from patients with no angina and single-vessel disease to
those with severe symptoms and advanced coronary disease
(10). Nevertheless our patients were at low cardiovascular
risk, with a mortality of 1% per annum in both groups.
The trial results therefore cannot be generalized to all
patients undergoing PCI but are relevant to a substantial
group of patients for whom optimal treatment has been
uncertain and for whom percutaneous intervention or con-
tinued medical therapy both seem appropriate.
Other trials of coronary angioplasty versus medical ther-
apy (4–8) provide important additional information but are
too small to reliably estimate the effects of the two treatment
Figure 4 Continued. For the medical group (C and D), the triangle indicates angina grade immediately before non-randomized intervention. CABG 
coronary artery bypass graft.
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strategies on mortality or risk of MI, and most have not
reported long-term follow-up data. The TIME and ACIP
trials are also relevant, but these trials compared a policy of
early myocardial revascularization with continued medical
therapy, and the long-term effects of percutaneous and
surgical treatment cannot easily be separated (13,14).
The clinical significance of MI during PCI has recently
been the subject of intense research interest. Some investi-
gators report that the extent of myonecrosis, defined by the
serum cardiac enzyme level, correlates closely with mortality
during long-term follow-up (15,16). Other studies suggest
that a small peri-procedural rise in cardiac enzyme level is
not of prognostic importance (17–19). In RITA-2, the
assigned coronary angioplasty procedures were associated
with a small risk of MI, but as we did not routinely measure
serum cardiac enzyme levels, the incidence of procedure-
related myocardial injury may have been underestimated.
Nevertheless, this procedural risk did not translate into
increased mortality during follow-up, and although RITA-2
was not designed to compare the effects of the two treat-
ments on long-term mortality, the data suggest that early
coronary intervention is a safe strategy in low-risk patients
with symptomatic CAD.
Many interventional cardiologists advocate dilation of
severe coronary stenoses irrespective of symptoms, in the
belief that this reduces the risk of progression to coronary
occlusion, prevents MI, and improves prognosis. Our data
do not support this belief, and in RITA-2, dilation of one or
more coronary stenoses did not subsequently affect the
incidence of MI or death over eight years of follow-up.
Patients with more extensive CAD may gain prognostic
benefit from coronary artery bypass surgery (20), but
whether contemporary PCI influences prognosis in such
patients can be elucidated only by additional randomized
clinical trials.
Angina and exercise tolerance. The RITA-2 data suggest
that the main advantage of PTCA over medical manage-
ment is an improved angina status and exercise tolerance
over many years, but the long-term symptom data require
careful interpretation. Shortly after randomization, there is
a substantial reduction in anginal symptoms among patients
treated by PTCA compared with patients assigned medical
therapy. Thereafter this treatment difference attenuates
because of symptomatic improvement in the medical man-
agement group, which can be largely explained by the effects
of myocardial revascularization procedures in 35% of med-
ical patients (Fig. 4). Thus, the intention-to-treat results for
angina prevalence (grade 2 or worse) at five years show only
30% proportionately fewer cases in the PTCA group com-
pared with the medical group. This narrowing of the
observed treatment difference over time should not be
interpreted as a decline in the effectiveness of an interven-
tional strategy but as an inevitable consequence of the most
severely affected medical group patients requiring coronary
interventions. More complex statistical modeling of these
issues has been undertaken and confirms this interpretation
(21).
It is relevant to note that the most powerful predictors of
symptomatic status at five years are breathlessness, exercise
time, and angina grade at baseline. Furthermore, more
severe angina grade at baseline is the strongest predictor of
cardiac death or MI. By comparison, there was no evidence
that other baseline variables, including the number of
diseased vessels and LV function score, predict subsequent
symptoms or cardiac events. This analysis has limited
statistical power but implies that the management strategy
for patients with coronary disease for which revasculariza-
tion is not considered essential on prognostic grounds can
be predominantly determined by symptoms. In RITA-2,
patients with mild symptoms at baseline had a better
prognosis, and among such patients the use of coronary
angioplasty and the associated procedural risk can reason-
ably be delayed until worsening symptoms mandate inter-
vention, particularly as the economic cost of the interven-
tional strategy exceeds the cost of conservative care (22).
Study limitations. The RITA-2 trial enrolled patients
from 1992 to 1996, since when there have been considerable
Table 2. Multivariate Predictors of Cardiac Death and
Non-Fatal MI, and Angina Grade 2 or Worse at Five Years
Cardiac Death and MI
Risk Factor
Hazard
Ratio 95% CI p Value
Treatment
Medical 1 –
PTCA 0.82 0.53 to 1.29 p  0.39
Angina grade
Grade 0 or 1 1 –
Grade 2 2.07 1.22 to 3.52
Grade 3 or 4 2.18 1.21 to 3.92 p  0.007
Diseased Proximal
(50% stenosis)
No LAD 1 –
LAD only 0.98 0.55 to 1.74
LAD  other 2.71 1.40 to 5.24 p  0.025
Angina Grade 2 at 5 Years*
Risk Factor
Odds
Ratio 95% CI p Value
Treatment
Medical 1 –
PTCA 0.67 0.47 to 0.97 p  0.031
Angina grade
0 or 1 1 –
2 1.18 0.77 to 1.81
3 or 4 1.17 0.71 to 1.93 p  0.71
Exercise time (mins)
9 1 –
6–9 1.63 1.02 to 2.61
6 2.80 1.72 to 4.56 p  0.001
Breathlessness
None 1 –
Mild 0.81 0.52 to 1.26
Severe 2.28 1.41 to 3.70 p  0.001
*Among 889/1,018 (87%): 64 patients did not have the baseline Bruce exercise test.
LAD  left anterior descending coronary artery. Other abbreviations as in Table 1.
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advances in both medical and interventional treatment. The
use of coronary stents has increased markedly, and develop-
ments in stent design and deployment techniques, together
with adjunctive use of clopidogrel and glycoprotein IIb/IIIa
receptor antagonists, have all contributed to improvements
in outcome after PCI (23,24). Randomized trials of multi-
vessel stenting versus CABG, such as ARTS (25),
ERACI-2 (26), and SOS (27) provide valuable information,
but their follow-up period is still relatively short. The
introduction of drug-coated stents has been heralded as a
major advance, but there are no data concerning the
long-term effects of this new technology (28). Other
changes in practice include increasing use of hydroxymethyl
glutaryl coenzyme A (HMG-CoA) reductase inhibitors
(29,30), angiotensin-converting enzyme inhibitors (31), and
thienopyridines (32) in patients with CAD.
The long-term prognostic and symptomatic implications
of all these developments for patients considered eligible for
PCI remain largely unexplored to date. The Clinical Out-
come Utilizing Revascularization and Aggressive Drug
Evaluation (COURAGE) trial is testing the hypothesis in
more than 3,000 patients that optimal catheter-based cor-
onary revascularization combined with intensive medical
therapy is superior to intensive medical therapy alone (33).
Further data will be available from the BARI-2D trial, a
comparison of medical therapy and revascularization in
patients with type 2 diabetes mellitus. These trials will be
important contributions; but recruitment in both trials is
ongoing, and hence, long-term results will not be known for
several years. Meantime RITA-2 provides the best currently
available insight into outcome many years after initial
policies of percutaneous intervention or conservative man-
agement in patients with angina.
Conclusions. In conclusion, we have demonstrated that
PTCA reduces anginal symptoms and improves exercise
tolerance in the long-term for patients who are considered
suitable for treatment by percutaneous intervention or by
continued medical therapy. However, among such patients
PTCA does not appear to influence the disease natural
history favorably with regard to risk of death and non-fatal
MI. Treatment choice can therefore be determined princi-
pally by symptom status. Patients with mild to moderate
angina can be safely managed with continued medical
therapy, but percutaneous intervention is appropriate if
symptoms are not controlled by medication. Other trial
evidence is needed to update these long-term findings
regarding percutaneous interventional treatment, in the
light of increased use of coronary stents and recent devel-
opments in medical treatments.
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APPENDIX
For a complete list of participants in the RITA-2 trial,
please see the October 1, 2003, issue of JACC at www.
cardiosource.com/jacc.html.
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